Immunovant, Inc.IMVTEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 55.30% | 79.8M | — | 2023-10-04 |
| FMR LLC | 8.56% | 12.5M | ▲ +3.12pp | 2024-11-12 |
| Deep Track Capital, LP | 0.69% | 1.0M | — | 2024-02-14 |
Insider Transactions
Net 90d: −$10.35M · buys $0 / sells $10.35MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-23 | Stout Jay S | Chief Technology Officer | Sell (open market) | 2.8K | $29.62 | $81.6K |
| 2026-04-23 | Tiago Girao | Chief Financial Officer | Sell (open market) | 25.8K | $29.62 | $763.0K |
| 2026-04-08 | Van Tuyl Christopher | Chief Legal Officer | Sell (open market) | 5.2K | $24.83 | $128.2K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell (open market) | 8.6K | $24.83 | $213.9K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell (open market) | 1.5K | $24.83 | $37.7K |
| 2026-04-08 | Melanie Gloria | Chief Operating Officer | Sell (open market) | 8.7K | $24.83 | $216.6K |
| 2026-04-07 | Hughes Douglas J. | Director | Grant | 13.9K | $0.00 | $0 |
| 2026-04-07 | Frank Torti | Director | Grant | 174.2K | $0.00 | $0 |
| 2026-04-07 | Jake Bauer | Director | Grant | 13.9K | $0.00 | $0 |
| 2026-04-07 | Atul Pande | Director | Grant | 13.9K | $0.00 | $0 |
1–10 of 25
Page 1 / 3